List of Genetic Analysis/Screening Companies with Phase 3 Active Clinical Trial - 20

ARCEDI Biotech ApS is a Danish biotech company involved in developing technologies for rare cell detection, a widely sought after application in the prenatal as well as cancer diagnostics. ARCEDI Biotech has proprietary method to enrich fetal cells from circulating maternal blood with high efficiency. Once enriched, the fetal cells can be utilized for downstream analysis using technologies such as FISH, 'Next Generation Sequencing', etc.

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

Carbiotix is an award-winning biotechnology company pioneering the onsite upcycling of plant-based side-streams. Carbiotix mission is to improve the health of people by increasing the consumption of prebiotics and other active ingredients from upcycled side-streams. Carbiotix offers one core service today called NutraCycle, an on-site upcycling and fortification service allowing food & beverage, ingredient, and feed producers to turn plant-based products into healthier, more profitable, and sustainable products.

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization.

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

Devyser. A new level of certainty We’re specialists when it comes to diagnostic kits for complex DNA testing within oncology, hereditary diseases and transplantation. Our products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics, as well as in post transplant follow-up. We have a guiding principle when it comes to developing products that are ideal for routine diagnostics: make the technology simple, reproducible and less prone to user-generated errors. And this is precisely what our customers appreciate about us, which is why routine diagnostic laboratories in more than 60 countries worldwide use our products.

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

Liquid biopsies provide better therapy options for more patients. Hedera Dx is on a mission to provide the next billion people with access to modern cancer care. We specialize in clinic-ready, NGS-based liquid biopsies that enable non-invasive diagnosis, timely treatment selection, and longitudinal disease monitoring. Our culture is based on thinking different, modern and human, fostering a dynamic and innovative work environment.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

At MyOme, we help families understand their DNA, and how it impacts their health throughout their lives, with secure and portable data using the latest technologies. We are always interested to hear from smart, passionate people with a background in bio stats, data science, and ML. Connect with us!

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.  Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Interested in joining us on our mission to change the management of disease worldwide? Visit https://www.natera.com/careers-at-natera to learn how you can become a part of our talented team. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Please be advised that Natera will reach out to candidates with an @natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes. https://www.natera.com/privacy/

OneOme, co-founded by Mayo Clinic, is working to help providers incorporate pharmacogenomics into patient care by offering the RightMed Test and associated tools. The RightMed Test may help providers optimize medication selection for their patients by analyzing and reporting on 27 genes. OneOme is privately held, based in Minneapolis, MN. For more information, visit www.oneome.com and follow us here for updates.

Ophiomics is a Biotech company developing new diagnostic products and services integrating bioinformatics and genomics in support of diagnostic, prognostic, pharmacogenomics and clinical follow up in liver cancer.

Phylos is a cannabis genetics company focused on helping growers of all sizes to succeed commercially with seeds that produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary technologies and its cultivation, extraction, and formulation expertise to provide partners with unparalleled THCV genetics and natural, safe and effective ingredients.

Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.

We are excited to continue to support women's health under the Labcorp name. Follow us @Labcorp

SOPHiA GENETICS is a healthcare company that specializes in genomics analysis using artificial intelligence and data analysis.

Takara Bio Inc. is committed to improving the human condition through biotechnology. Starting as the biomedical business of Takara Shuzo, a fermentation and beverage company founded in 1925 (now Takara Holdings Company, Inc.), Takara Bio has focused on developing research tools for the life sciences, cell and gene therapy technologies, and nutraceuticals since its launch in 1967. The three business units of TAKARA BIO INC are: • Genetic Engineering Research - manufactures and sells research reagents and scientific instruments used by biotechnology researchers worldwide, as well as contract research services. • Agribio - produces and sells health food products whose functionality have been proven by biotechnology, and conducts a mushroom business based on technologies for large-scale mushroom production. • Gene Medicine - conducts clinical development projects to work toward commercializing cell and gene therapies centered on a highly efficient gene transduction method and a lymphocyte expansion-culture system, both using RetroNectin® reagent.

Zambon is a modern healthcare company founded on the history and values of an Italian family and committed to innovating cure & care to improve patients’ lives. Zambon is present in three different Continents – Europe, America and Asia – with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon SpA, the pharma subsidiary of the group with its 23 branches, has taken a new role in the industry. In addition to pain and diseases of the respiratory system and urological system, Zambon is establishing a global pipeline and introducing important treatments for serious diseases such as Parkinson’s Disease, Cystic Fibrosis, BOS and NCFB. In recent years, ZBiotech, a specialized biotech company that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through through the scouting, acquisition, licensing and development of new molecules, has also been established. Zambon produces high quality products thanks to the management of the whole production chain which involves Zach-Zambon Chemicals, a privileged partner for API, custom synthesis and generic products. Zambon complements the offering of medicines with modern health solutions, in order to translate its Vision into concrete actions. Zcube - Zambon Research Venture - is actively scouting for modern health solutions in the field of drug delivery systems, medical devices, biomarkers, diagnostics, digital health and big data solutions. In 2018 Zcube established Careapt, a new start-up which develops integrated Hi-Tech/Hi-Touch solutions for chronic disease management. The group also includes ItaliAssistenza, a Home Care Company involved in Patient Support Programs and home care. Zambon was established in 1906 in Vicenza and is headquartered in Milan within OpenZone, the scientific campus where knowledge is shared between partners in the field of Healthcare, founded with the aim to transform research into enterprise.